scPharmaceuticals’ (NSDQ:SCPH) has signed a development agreement to incorporate West Pharmaceutical Services’(NYSE:WST) SmartDose drug delivery system with Furoscix, a drug that scPharmaceuticals developed to treat edema in heart failure patients. Burlington, Mass.-based scPharmaceuticals recently completed preliminary feasibility studies of the drug-device combination. The testing included drug stability in the pre-filled cartridge, drug compatibility, and overall performance within […]
scPharmaceuticals
scPharmaceuticals names Tucker as CEO | Personnel Moves – May 1, 2017
scPharmaceuticals said in late April that it named pharma-veteran John Tucker as president & CEO, effective immediately. Tucker was also elected to the company’s board of directors. Tucker formerly served as CEO of Alcresta, where he led regulatory and financing strategies for the company’s 1st product approval and launch. He also worked as Incline Therapeutics’ […]
scPharmaceuticals closes $46m Series B round
scPharmaceuticals said today that it closed a $45.6 million Series B round, co-led by OrbiMed and a subsidiary of Sun Pharmaceutical Industries. Other investors included 5AM Ventures and Lundbeckfond Ventures. The investment will be used to support the development of the operational and commercial infrastructure needed to bring Furoscix and the sc2Wear Infusor to market […]
Jawbone agrees to pony up more than $100M for BodyMedia’s wearable sensors | Wall Street Beat
Jawbone agreed to acquire BodyMedia, reportedly for more than $100 million, in a bid to expand its footprint in the wearable technology market.
San Francisco-based Jawbone did not disclose the deal’s value, but Reuters, citing "a person familiar with the matter," reported that it’s worth "north of $100 million."
Pittsburgh-based BodyMedia’s roughly 60 employees will "join Jawbone’s existing team," according to a press release.
